

Aripiprazole-induced Tardive Dyskinesia in 13 Years Old Girl Successfully Treated with Biperiden: A Case Report

Marco Lamberti^{1,2}, Gabriella Di Rosa¹, Francesca Cucinotta¹, Erica Pironti¹, Cecilia Galati¹, Antonella Gagliano¹

¹Division of Child Neurology and Psychiatry, Department of Pediatrics, ²Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy

In the last years second-generation antipsychotics are increasingly prescribed in the pediatric population for the treatment of several psychiatric disorders. Among the long term adverse effects, extrapyramidal symptoms (EPS) are less reported compared to first-generation antipsychotics. Tardive dyskinesia (TD) is a iatrogenic rare syndrome characterized by persistent slow writhing and sudden involuntary movements mainly involving the oral-buccal-lingual area with masticatory movements. We report a young girl with mood disorders accompanied by mild intellectual disability and behavioral problems who had TD after treatment with Aripiprazole, which responded to Biperiden therapy.

KEY WORDS: Antipsychotics; Drug side effects; Tardive dyskinesia; Movement disorders; Pediatrics.

INTRODUCTION

Tardive dyskinesia (TD) is a rare syndrome characterized by persistent slow writhing and sudden involuntary movements mainly involving the oral-buccal-lingual area with masticatory movements.^{1,2)} TD is considered a iatrogenic disorder mostly associated with long-term use of first generation antipsychotics and most often observed in women and middle-old aged patients after a minimal interval of exposure of 3 months.^{1,3-5)} In the last years, it has been accepted that TD may appear relatively early in the course of treatment with dopamine receptor blocking agents (DRBAs).¹⁾ However, such extrapyramidal symptoms (EPS) are less reported in patients undertreated with second-generation antipsychotics (SGAs).⁶⁾ Aripiprazole is an atypical antipsychotic with partial dopamine D2 receptor agonist, 5HT 1A agonist and 5HT 2A antagonist properties.⁷⁾ The high occupancy of D2 receptors occurs without inducing EPS in the majority of subjects since partial agonism induces a lower functional antagonism of

D2 receptor-mediated neurotransmission, rather than full antagonists.⁸⁾ To date, few cases of TD have been reported in patients treated with aripiprazole and most of them were adults in association with other manifestations such as parkinsonism or after long-term treatment and exposure to many different drugs.^{5,9-13)} Here we present a case report of a 13-years-old girl who developed TD after a 3-weeks-treatment with aripiprazole.

CASE

A 9-years-old girl was referred, for the first time, to our unit for behaviour and mood disorders accompanied by mild intellectual disability. The patient had a history of slight delayed motor, language and social milestones. According to mother she was a difficult child to manage during infancy as she had behaviour problems. Learning difficulties and verbal speech impairment had been managing with special education programs, cognitive therapy and logotherapy. The neurological examination failed to reveal major pathological signs. A complete diagnostic work-up for intellectual disability was performed including: routine laboratory investigations, coagulation and metabolic exams that resulted to be unremarkable. Neurophysiological investigations including electroencephalography (EEG), visual evoked potential and auditory brainstem response (ABR) were normal. Karyotype was 46,XX. Array-CGH failed to show any abnormalities.

Received: April 22, 2016 / **Revised:** May 25, 2016

Accepted: June 16, 2016

Address for correspondence: Marco Lamberti, MD
Division of Child Neurology and Psychiatry, Department of Pediatrics, Department of Clinical and Experimental Medicine, University of Messina, Policlinico Universitario G. Martino, Via Consolare Valeria 1, 98125 Messina, Italy
Tel: +39-090-2212910, Fax: +39-090-2930414
E-mail: mlamberti@unime.it; marcolb@yahoo.it

© This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Brain magnetic resonance imaging scan was normal. At age of 11 she showed a worsening of behavioural problems characterized by marked irritability, mood instability characterized by frequent fluctuations of mood over time, changes in eating, compulsive self-biting and obsessive thoughts, several sleep-related movement disorders included bruxism, body rolling and enuresis. She was treated with valproate and topiramate for around six months with no effect. Valproate and topiramate were discontinued while risperidone was introduced at starting dose of 0.5 mg/day and then increased to 2 mg/day, with improvement of behavioral symptoms. Nevertheless, one year later, the patient presented a worsening of mood instability and of temper outbursts (verbally and behaviorally). Thus, risperidone was gradually withdrawn and quetiapine was started at initial dose of 100 mg/day up to 300 mg/day with beneficial. One year later, due to a further relapse of psychiatric symptoms, the patient was referred to another clinical center where quetiapine was stopped and aripiprazole was started at 7.5 mg/day as initial dose. After 3 weeks, the girl displayed involuntary movements of her mouth and slurred speech. For this reason her parents abruptly suspended aripiprazole. After 2 days she was referred to our unit for the occurrence of fine and rhythmic lips movements, along the vertical axis. Also the tongue was involved with constant rhythmic dystonic contractures. The clinical examination did not reveal any other EPS.

A concomitant video-EEG recording failed to show epileptiform discharges. The patient was immediately treated with clonazepam (4 mg/day) for 3 days without efficacy. After further 3 days with antioxidants (vitamin E) supplementation, with poor results, we decided to start biperiden 2 mg/day. It induced rapid reduction and disappearance of clinical symptoms within 3 weeks.

DISCUSSION

In a recent systematic review, annual TD incidence rate in children was reported to be 0.35% with SGAs.¹⁴⁾ Although the occurrence of EPS seems to be less frequent with atypical antipsychotics, surveillance of their appearance is recommended, especially if specific risk factors such as pediatric age, female sex, affective disorder diagnosis do exist.¹⁵⁾ The incidence of EPS differs among SGAs with a major rate reported in patients treated with risperidone, to a lesser extent in those with clozapine and quetiapine.¹⁶⁾ The likelihood of developing EPS with a first-line SGA depends not only on the specific agent, but

also on the rapidity of dose escalation, the target dose, and the patient's intrinsic vulnerability to EPS.¹⁶⁾

To date, report of TD in patients treated with atypical antipsychotics is rare and, to the best of our knowledge, there are only few reported cases of TD related to aripiprazole.^{9-11,13)} All of the patients reported were adults and only in one case TD emerged after at least 2 months of aripiprazole therapy.¹³⁾ Conversely, some authors showed efficacy of aripiprazole to treat TD induced by other DRBAs.¹⁷⁻¹⁹⁾ These authors supported the use of aripiprazole according to its peculiar mechanism of action²⁰⁾ by which it exerts activity as a dopamine agonist in hypodopaminergic states, while it acts as a dopamine antagonist when dopaminergic activity is increased. In this view, it may play a role in both prevention and treatment of TD.

Our patient presented two risk factors for TD such as female sex and an affective disorder. Although the semiology of the movements was quite suggestive, her manifestations atypically started after short term aripiprazole treatment. Nevertheless, our patient received quetiapine as long term treatment before starting aripiprazole, thus, her chronic previous quetiapine-exposure could contribute to TD. TD must be distinguished from rabbit syndrome (RS). In fact, even if RS is also a iatrogenic disorder, the movements observed in RS are rapid and regular, not involve the tongue and cannot be voluntary suppressed by the patient.²¹⁾ Furthermore TD has to be distinguished from other movements involving the face and the mouth regions such as orofacial tics (e.g., Tourette's syndrome), orofacial tremors (e.g., parkinsonian tremors), orofacial dystonia (e.g., Meige syndrome) and orofacial chorea.¹⁾ Differential diagnosis is crucial to identify the appropriate treatment of TD. Bhidayasiri *et al.*²²⁾ find out three levels of evidence-based recommendations of treatment of TD, but most of the agents are not recommended for pediatric population.

Although aripiprazole and quetiapine are characterized by a relatively low incidence of EPS, the present case underlines that clinicians should screen for EPS all patients in treatment with SGAs, since the first weeks of drug exposure. According to the American Academy of Neurology guidelines²²⁾ after withdrawing aripiprazole therapy, we started clonazepam (Level B of recommendation). Since no improvements were gained, we could not prescribe another antipsychotic given the young age of the patient. After failing antioxidant supplementation, we decided to start biperiden (both Level U of recommendation). Although it is not specifically recommended in treatment of TD, efficacy of biperiden has been pre-

viously reported in a young girl with severe dyskinesia induced by phenytoin.²³⁾

In conclusion, our 13-years-old patient with TD induced by aripiprazole showed rapid and complete improvement with biperiden treatment. Although few reports in the literature support this evidence, treatment with biperiden would be considered to manage TD in paediatric population. Moreover, video-EEG reports of such patients may be useful to improve diagnostic accuracy of this rare EPS in childhood.

■ Acknowledgments

The authors thank the patient and her family for collaboration to the study.

REFERENCES

1. Aia PG, Revuelta GJ, Cloud LJ, Factor SA. *Tardive dyskinesia*. *Curr Treat Options Neurol* 2011;13:231-241.
2. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R, Annable L. *Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia*. *Can J Psychiatry* 2005;50:703-714.
3. Schwartz T, Raza S. *Aripiprazole (abilify) and tardive dyskinesia*. *P T* 2008;33:32-34.
4. Novick D, Haro JM, Bertsch J, Haddad PM. *Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study*. *J Clin Psychopharmacol* 2010;30:531-540.
5. Baldessarini RJ, Gardner DM. *Incidence of extrapyramidal syndromes and tardive dyskinesia*. *J Clin Psychopharmacol* 2011;31:382-384; author reply 384-385.
6. Correll CU, Leucht S, Kane JM. *Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies*. *Am J Psychiatry* 2004;161:414-425.
7. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. *Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology*. *Neuropsychopharmacology* 2003;28:1400-1411.
8. Di Sciascio G, Riva MA. *Aripiprazole: from pharmacological profile to clinical use*. *Neuropsychiatr Dis Treat* 2015;11:2635-2647.
9. Goyal R, Devi SH. *A case of aripiprazole induced tardive dyskinesia in a neuroleptic-naïve patient with two years of follow up*. *Clin Psychopharmacol Neurosci* 2014;12:69-71.
10. Lim HK, Pae CU, Lee C, Lee CU. *Tardive dystonic symptoms associated with aripiprazole treatment*. *Prog Neuropsychopharmacol Biol Psychiatry* 2008;32:589-590.
11. Moseley CN, Simpson-Khanna HA, Catalano G, Catalano MC. *Covert dyskinesia associated with aripiprazole: a case report and review of the literature*. *Clin Neuropharmacol* 2013;36:128-130.
12. Patra S. *Tardive dyskinesia and covert dyskinesia with aripiprazole: a case series*. *Curr Drug Saf* 2016;11:102-103.
13. Wang LJ, Ree SC, Chen CK. *Courses of aripiprazole-associated tardive dyskinesia: report of two cases*. *Prog Neuropsychopharmacol Biol Psychiatry* 2009;33:743-744.
14. Correll CU, Schenk EM. *Tardive dyskinesia and new antipsychotics*. *Curr Opin Psychiatry* 2008;21:151-156.
15. Peña MS, Yalho TC, Jankovic J. *Tardive dyskinesia and other movement disorders secondary to aripiprazole*. *Mov Disord* 2011;26:147-152.
16. Weiden PJ. *EPS profiles: the atypical antipsychotics are not all the same*. *J Psychiatr Pract* 2007;13:13-24.
17. Kang NR, Kim MD. *Tardive dyskinesia: treatment with aripiprazole*. *Clin Psychopharmacol Neurosci* 2011;9:1-8.
18. Lykouras L, Rizos E, Gournellis R. *Aripiprazole in the treatment of tardive dyskinesia induced by other atypical antipsychotics*. *Prog Neuropsychopharmacol Biol Psychiatry* 2007;31:1535-1536.
19. Osorio RS, Agüera-Ortiz L, Hurtado de Mendoza A, Ramos I, Palomo T. *Treatment of tardive dyskinesia with aripiprazole*. *Neurotox Res* 2010;17:432-434.
20. Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S. *Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study*. *Am J Psychiatry* 2007;164:1411-1417.
21. Catena Dell'osso M, Fagiolini A, Ducci F, Masalehdan A, Ciapparelli A, Frank E. *Newer antipsychotics and the rabbit syndrome*. *Clin Pract Epidemiol Ment Health* 2007;3:6.
22. Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA; American Academy of Neurology. *Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology*. *Neurology* 2013;81:463-469.
23. Caksen H, Odabaş D, Anlar O. *Use of biperiden hydrochloride in a child with severe dyskinesia induced by phenytoin*. *J Child Neurol* 2003;18:494-496.